ACA
GILD icon

Ackerman Capital Advisors’s Gilead Sciences GILD Stock Holding History

Ackerman Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,000
Closed -$390K – 123
2019
Q4 		$390K Buy
6,000
+2,500
+71% +$163K 0.12% 116
2019
Q3 		$222K Buy
+3,500
New +$229K 0.08% 125

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ackerman Capital Advisors's GILD Position: Q1 2020 in Review

Ackerman Capital Advisors sold out of Gilead Sciences (GILD) in Q1 2020, closing a stake of 6,000 shares — an estimated $390K sold.

Ackerman Capital Advisors first reported a position in GILD in Q3 2019 and held it in 2 quarters. The position peaked at $390K in Q4 2019. 1,643 funds tracked by Wall St. Rank hold GILD as of Q1 2020.

  • Ackerman Capital Advisors reported no remaining Gilead Sciences position as of Q1 2020 after selling out during the quarter.
  • Ackerman Capital Advisors sold 6,000 Gilead Sciences shares in Q1 2020, an estimated $390K.
  • Ackerman Capital Advisors first reported a position in Gilead Sciences in Q3 2019 and held it in 2 quarters.
  • Ackerman Capital Advisors's Gilead Sciences position peaked at $390K in Q4 2019.
  • 1,643 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2020.

Based on Ackerman Capital Advisors's 13F filing for Q1 2020, filed 14 Aug 2020.